Drug Profile
Minocycline - Hovione
Alternative Names: HY-02; MeizuvoLatest Information Update: 16 Oct 2021
Price :
$50
*
At a glance
- Originator Hovione
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action Glial cell inhibitors; Interleukin 1 alpha inhibitors; Interleukin-6 modulators; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Eye disorders
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Eye-disorders in Ireland (Topical, Ointment)
- 17 Mar 2021 Adverse events and efficacy data from a phase II trial in Eye disorders released by Hovione
- 18 Sep 2020 Hovione Scientia completes a phase II trial in Eye disorders in the USA (NCT03888378)